Clinical Trials
3 trialsNCT04862780 2025-02-10
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04959981 2023-07-25
HERKULES-2
Erasca, Inc.
Phase 1 Completed
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated